Shots:

• Roche to receive upfront- development and commercial milestone payments plus royalties and retains option to license for each ex-China development and commercialization. Innovent to get non-exclusive access to certain technologies of Roche to discover and develop specific 2:1 T-cell bispecific Abs (TCB) and the universal CAR-T platform
• If Roche exercise the option- it will pay $140M as exercise fee- additional development- approval- sales milestone payments up to $1.96B (if all products are successfully developed and commercialized) plus royalties on each product to Innovent
• Roche's 2:1 T-cell bispecific Ab platform targeted to discover- develop and commercialize novel bispecific molecules including cell therapies for hematological and solid cancers

Click here to read full press release/ article 

Ref: Roche | Image:  Roche